Literature DB >> 26989820

Advances in pleural diseases: what is the future for medical thoracoscopy?

Pyng Lee1, Praveen N Mathur.   

Abstract

PURPOSE OF REVIEW: Medical thoracoscopy provides the physician a window into the pleural space. The procedure allows biopsy of the parietal pleura under direct visualization with good accuracy. In addition, it achieves therapeutic goals of fluid drainage, guided chest tube placement, and pleurodesis. RECENT
FINDINGS: Comparable diagnostic yield is achieved with the flexi-rigid pleuroscope even though pleural biopsies are smaller using the flexible forceps as compared to rigid thoracoscopy. Flexi-rigid pleuroscopy is extremely well tolerated and can be performed safely as an outpatient procedure. Biopsy quality can be further enhanced with accessories that are compatible with the flex-rigid pleuroscope such as the insulated tip knife and cryoprobe.
SUMMARY: With more sensitive tools to image the pleura such as contrast-enhanced computed tomography, MRI, ultrasonography, PET, increased yield with image-guided biopsy as well as advances in cytopathology, what lies in the future for medical thoracoscopy remains to be seen. However, it is the authors' opinion that medical thoracoscopy will evolve with time, complement novel techniques, and continue to play a pivotal role in the evaluation of pleuropulmonary diseases.

Entities:  

Mesh:

Year:  2016        PMID: 26989820     DOI: 10.1097/MCP.0000000000000265

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  2 in total

1.  Flex-rigid pleuroscopic biopsy with the SB knife Jr is a novel technique for diagnosis of malignant or benign fibrothorax.

Authors:  Xiao-Bo Wang; Yan Yin; Yuan Miao; Ralf Eberhardt; Gang Hou; Felix J Herth; Jian Kang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Evolution of medical thoracoscopy in developing countries.

Authors:  Nasir Siddique; Tajwar Nasir
Journal:  Pak J Med Sci       Date:  2017 Jan-Feb       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.